Related Experiment Video

Updated: Jul 3, 2026

The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice

Mugimane G Manjanatha1, Sharon D Shelton, Vasily N Dobrovolsky

  • 1Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas, USA. mugimane.manjanatha@fda.hhs.gov

Environmental and Molecular Mutagenesis
|July 12, 2008
PubMed

Insights

Methylphenidate hydrochloride (MPH), a common ADHD medication, did not show genotoxicity in B6C3F1 mice despite causing liver hypertrophy. Further studies confirmed no significant increase in mutations or micronuclei, indicating MPH is not genotoxic in this model.

Area of Science:

  • Pharmacology and Toxicology
  • Genetics and Molecular Biology
  • Pediatric Medicine

Background:

  • Methylphenidate hydrochloride (MPH) is a widely prescribed medication for Attention Deficit Hyperactivity Disorder (ADHD) in children.
  • Previous studies indicated a potential link between MPH treatment and increased hepatic adenomas in B6C3F1 mice.
  • Understanding the pharmacokinetics and genotoxicity of MPH and its metabolite, ritalinic acid (RA), is crucial for safety assessment.

Purpose of the Study:

  • To investigate the pharmacokinetics (PK) of MPH and its metabolite RA in male B6C3F1 mice.
  • To evaluate the genotoxicity of MPH through micronucleus tests and Hprt mutant frequency assays.
  • To determine the safety profile of MPH in relation to observed liver changes in mice.

Main Methods:

  • Pharmacokinetic analysis of MPH and RA serum concentrations after single oral gavage in mice.
  • 28-day dietary administration of MPH to determine dose ranges for genotoxicity studies.
  • In vivo genotoxicity assays including micronucleus test (MN-RETs, MN-NCEs) and Hprt mutant frequency in peripheral blood and splenic lymphocytes.

Main Results:

  • MPH administration led to significant liver weight increases (hypertrophy) in mice.
  • No significant increases in Hprt mutant frequency or micronucleus formation were observed in MPH-treated mice.
  • Significant body weight loss and decreased organ weights (kidneys, testes, thymus) were noted at the highest MPH dose (4,000 ppm).

Conclusions:

  • MPH induces liver hypertrophy in B6C3F1 mice but does not demonstrate genotoxicity.
  • The study provides evidence against MPH causing DNA damage or mutations in the tested models.
  • Findings suggest that observed liver changes may be adaptive responses rather than indicators of carcinogenic potential.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...